AN IN-VITRO AND IN-VIVO STUDY OF ANTITUMOR EFFECTS OF GENISTEIN ON HORMONE-REFRACTORY PROSTATE-CANCER

Hormone refractory prostate cancer remains an incurable disease. Newer agents with more activity are required. Genistein is a flavone compou nd with anti-tumor activity against various tumor systems in vitro. Th is study is undertaken to assess the efficacy of genistein against hor mone refractory prostate cancer. In vitro, genistein appears to be cyt otoxic to both the rat prostate cancer cell line MAT-LyLu and the huma n prostate adenocarcinoma cell fine, PC-3. In vivo, however; genistein failed to significantly inhibit the growth of subcutaneously implante d MAT-LyLu cells. More information regarding the pharmacokinetics and bid-availability of genistein is needed to determine if this is an act ive agent in human metastatic prostate cancer.